DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Afinitor (Everolimus) - Summary



AFINITOR (everolimus), an inhibitor of mTOR, is an antineoplastic agent.

AFINITOR® is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.

See all Afinitor indications & dosage >>


Media Articles Related to Afinitor (Everolimus)

Novartis drug Afinitor significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET
Source: Endocrinology News From Medical News Today [2015.09.30]
Novartis has announced results of a Phase III pivotal study showing Afinitor® (everolimus) tablets reduced the risk of progression by 52% (hazard ratio [HR] = 0.

FDA OKs New Kids' Dose of Cancer Drug
Source: MedPage Today Product Alert [2012.08.30]
WASHINGTON -- The FDA has approved a pediatric dosage of the cancer drug everolimus (Afinitor Disperz) for the treatment of a rare brain tumor.

Everolimus First Drug to Show Effect in Lung NETs
Source: Medscape Hematology-Oncology Headlines [2015.10.01]
Already approved for use in pancreatic neuroendocrine tumors (NETs), the drug now shows efficacy in tumors originating in lung and gastrointestinal tract.
Medscape Medical News

Promising Tx in GI Neuroendocrine Tumors
Source: MedPage Today Gastroenterology [2015.09.27]
(MedPage Today) -- Significant boosts in PFS with radiopharmaceutical, everolimus

more news >>

Published Studies Related to Afinitor (Everolimus)

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. [2014]
continuing 4-year extension phase of EXIST-1... INTERPRETATION: These results support the longer-term use of everolimus in

A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients. [2014]
Everolimus, an oral inhibitor of mammalian target of mTOR, has been recently shown to have antitumor effect in a phase III, double-blind, randomized trial (RADIANT-3) of 410 patients with advanced pancreatic neuroendocrine tumors (PNETs). The purpose of this study was to investigate the specific efficacy and safety of everolimus in the Chinese patient with PNETs...

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. [2013]
subependymal giant cell astrocytomas associated with tuberous sclerosis complex... INTERPRETATION: These results support the use of everolimus for subependymal

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [2013]
this patient population... CONCLUSION: The addition of everolimus to exemestane markedly prolonged PFS in

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. [2013]
gastric cancer... CONCLUSION: Compared with BSC, everolimus did not significantly improve overall

more studies >>

Clinical Trials Related to Afinitor (Everolimus)

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the combination vorinostat given in combination with either sirolimus, everolimus or temsirolimus that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) [Completed]
Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures, mental retardation and autism, and exhibiting a high variability in clinical findings both among and within families. Investigators are doing research in order to identify possible neurocognitive benefits from treatment with RAD001 or placebo for a six month period. There may also be potential for improvements in seizure frequency, sleep and autistic behaviors. We hope this trial will lead to a better understanding of TSC and to new forms of treatment, to benefit children and adults with TSC in the future. Individuals diagnosed with TSC will be asked to participate in this study if they are between the ages of 6 and 21 years of age and have an IQ of greater than or equal to 60. Both males and females will be asked to participate. Additionally, to be eligible for study participation, individuals must have been on the same seizure medication(s), if applicable, for at least 6 months. Individuals must also be able to participate in neuropsychological testing and meet certain medical criteria. They will need to sign an informed consent. If enrolled in the study, participants will have a number of screening tests to help determine if they are eligible for participation in the clinical trial. If eligible for the treatment phase of the trial, they will be asked to take either the study drug or a placebo (pill with no medicine), which is determined by chance. The study involves about 9 visits, 3 of which can be done locally, over a six month period, as well as follow-up calls with our research nurse. Study visits will vary in length. Screening, three month and six month visits may last up to 8 hours, while all other visits will be less than 2 hours. The study visits include blood draws, laboratory tests and neuropsychological assessments. There is no fee to participate in this study. Some compensation may be available for travel costs of out-of-state participants based on fund availability. The study drug will be provided at no charge during the study. After all study data has been analyzed, families will be informed of the overall results. Treatment on this study may or may not improve a child's learning skills (neurocognition). Future patients may benefit from what is learned.

Dose Finding Study of RAD001 (Everolimus, Afinitor´┐Ż) in Combination With BEZ235 in Patients With Advanced Solid Tumors [Completed]
Study has two parts: 1. Dose-finding: to determine the maximum tolerated dose (MTD) and to evaluate the safety and tolerability of RAD001 (everolimus , Afinitor®) in combination with BEZ235 in patients with advanced solid tumors. 2. Dose-expansion: to assess safety and tolerability of RAD001 and BEZ235 at the MTD in patients with ER+/HER2- metastatic breast cancer and metastatic renal cell cancer

Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression [Not yet recruiting]
The goal of this clinical research study is to find the highest tolerable dose of ceritinib (LDK378) and everolimus that can be given to patients with NSCLC or head and neck cancer. The safety of the drug combination will also be tested.

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer [Recruiting]
This study consists of two parts. In a phase Ib part, investigators will explore the recommended dose of gemcitabine, cisplatin, and RAD001 combination in patients with metastatic TNBC. After completing the phase Ib part, investigators will review the data and discuss with Novartis before the start of a phase II part. In the phase II part, investigators will compare the efficacy of the gemcitabine and cisplatin with or without RAD001 in patients with metastatic TNBC.

more trials >>

Reports of Suspected Afinitor (Everolimus) Side Effects

Neoplasm Malignant (362)Neoplasm Progression (337)Death (296)Fatigue (196)Dyspnoea (190)Pyrexia (173)Diarrhoea (150)Cough (123)Pneumonia (119)Anaemia (113)more >>

Page last updated: 2015-10-01

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015